| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| LIV-1 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Colorectal cancer,Breast cancer |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ladiratuzumab vedotin | SGN-LIV1A; MK-6440; MK6440 | Phase 2 Clinical | Merck Sharp & Dohme Corp, Seagen Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Melanoma; Metastatic breast cancer; Prostatic Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Laventatug | BRY-812 | Phase 2 Clinical | Zhejiang BioRay Biopharmaceuticals Co Ltd | Neoplasms; Solid tumours | Details |
